The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Blood

• Publication date

  2003-07-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1182/BLOOD-2002-09-2975PMID 12637321
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• An Inducible Pathway for Degradation of FLIP Protein Sensitizes Tumor Cells to TRAIL-induced Apoptosis*

  2002cited by this paper
• A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies.

  2002cited by this paper
• The short splice form of Casper/c‐FLIP is a major cellular inhibitor of TRAIL‐induced apoptosis

  2002cited by this paper
• Accelerated degradation of cellular FLIP protein through the ubiquitin-proteasome pathway in p53-mediated apoptosis of human cancer cells

  2001cited by this paper
• Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition.

  2001cited by this paper
• TRAIL expression by activated human CD4(+)V alpha 24NKT cells induces in vitro and in vivo apoptosis of human acute myeloid leukemia cells.

  2001cited by this paper
• TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications.

  2001cited by this paper
• Novel therapies targeting the myeloma cell and its bone marrow microenvironment.

  2001cited by this paper
• High-dose chemotherapy and hematopoietic stem cell transplantation for breast cancer: past or future?

  2001cited by this paper
• Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome.

  2001cited by this paper
• The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.

  2001cited by this paper
• Control of oncogenesis and cancer therapy resistance by the transcription factor NF-κB

  2001cited by this paper
• The proteasome: a new target for novel drug therapies.

  2001cited by this paper
• Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB.

  2001cited by this paper
• Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma.

  2001cited by this paper
• NF-κB Inducers Upregulate cFLIP, a Cycloheximide-Sensitive Inhibitor of Death Receptor Signaling

  2001cited by this paper
• The Restricted Expression of Granzyme M in Human Lymphocytes1

  2001cited by this paper
• Proteasome inhibition in cancer: development of PS-341.

  2001cited by this paper
• The Role of NF-κB in TNF-Related Apoptosis-Inducing Ligand (TRAIL)-Induced Apoptosis of Melanoma Cells1

  2001cited by this paper
• Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-kappaB.

  2001cited by this paper
• Three-color flow cytometric assay for the study of the mechanisms of cell-mediated cytotoxicity.

  2001cited by this paper
• Proteasome inhibition measurements: clinical application.

  2000cited by this paper
• The Rel/NF-kappaB family directly activates expression of the apoptosis inhibitor Bcl-x(L).

  2000cited by this paper
• T cell lysis of murine renal cancer: multiple signaling pathways for cell death via Fas

  2000cited by this paper
• Inhibition of NF-κB Activity Enhances TRAIL Mediated Apoptosis in Breast Cancer Cell Lines

  2000cited by this paper
• Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341.

  2000cited by this paper
• Human brain-cell death induced by tumour-necrosis-factor-related apoptosis-inducing ligand (TRAIL)

  2000cited by this paper
• TNF-related apoptosis-inducing ligand (TRAIL) as a negative regulator of normal human erythropoiesis.

  2000cited by this paper
• The Rel/NF-κB Family Directly Activates Expression of the Apoptosis Inhibitor Bcl-xL

  2000cited by this paper
• Requirement for Casper (c-FLIP) in regulation of death receptor-induced apoptosis and embryonic development.

  2000cited by this paper
• Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant Group.

  2000cited by this paper
• Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand

  2000cited by this paper
• NF-kappa B does not modulate sensitivity of renal carcinoma cells to TNF alpha-related apoptosis-inducing ligand (TRAIL).

  2000cited by this paper
• Inhibition of NF-kappaB activity enhances TRAIL mediated apoptosis in breast cancer cell lines.

  2000cited by this paper
• Safety and antitumor activity of recombinant soluble Apo2 ligand.

  1999cited by this paper
• Cell cycle-dependent regulation of FLIP levels and susceptibility to Fas-mediated apoptosis.

  1999cited by this paper
• TRAIL is a potent inducer of apoptosis in myeloma cells derived from multiple myeloma patients and is not cytotoxic to hematopoietic stem cells

  1999cited by this paper
• Tumor Necrosis Factor-related Apoptosis-inducing Ligand Receptors Signal NF-κB and JNK Activation and Apoptosis through Distinct Pathways*

  1999cited by this paper
• Proteasome inhibitors: a novel class of potent and effective antitumor agents.

  1999cited by this paper
• Tumor necrosis factor-related apoptosis-inducing ligand receptors signal NF-kappaB and JNK activation and apoptosis through distinct pathways.

  1999cited by this paper
• Tumoricidal activity of tumor necrosis factor–related apoptosis–inducing ligand in vivo

  1999cited by this paper
• The prosurvival Bcl-2 homolog Bfl-1/A1 is a direct transcriptional target of NF-kappaB that blocks TNFalpha-induced apoptosis.

  1999cited by this paper
• The prosurvival Bcl-2 homolog Bfl-1/A1 is a direct transcriptional target of NF-κB that blocks TNFα-induced apoptosis

  1999cited by this paper
• IEX-1L, an apoptosis inhibitor involved in NF-kappaB-mediated cell survival.

  1998cited by this paper
• IEX-1L, an Apoptosis Inhibitor Involved in NF-κB-Mediated Cell Survival

  1998cited by this paper
• Inhibition of nuclear factor kappaB activation attenuates apoptosis resistance in lymphoid cells.

  1998cited by this paper
• TNF-related apoptosis-inducing ligand (TRAIL) induces apoptosis in Fas ligand-resistant melanoma cells and mediates CD4 T cell killing of target cells.

  1998cited by this paper
• NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation.

  1998cited by this paper
• Guide for the Care and Use of Laboratory Animals

  1996cited by this paper
• Leukemia relapse after allogeneic bone marrow transplantation: a review.

  1994cited by this paper
• Treatment of testicular cancer: a new and improved model.

  1990cited by this paper
• Interpretation of clinical trials in diffuse large-cell lymphoma.

  1988cited by this paper

• In Silico, In Vitro, and In Vivo Evaluation of Caffeine-Coated Nanoparticles as a Promising Therapeutic Avenue for AML through NF-Kappa B and TRAIL Pathways Modulation

  2023cites this paper
• Harnessing natural killer cells for the treatment of multiple myeloma.

  2022cites this paper
• Harnessing TRAIL-Induced Apoptosis Pathway for Cancer Immunotherapy and Associated Challenges

  2021cites this paper
• TRAIL therapy and prospective developments for cancer treatment.

  2020cites this paper
• Accelerated degradation of cFLIPL and sensitization of the TRAIL DISC-mediated apoptotic cascade by pinoresinol, a lignan isolated from Rubia philippinensis

  2019cites this paper
• TRAIL responses are enhanced by nuclear export inhibition in osteosarcoma.

  2019cites this paper
• Natural Killer Cell-Based Immunotherapy in Gynecologic Malignancy: A Review

  2018cites this paper
• 2 Resistance to Apoptosis in Cancer Therapy

  2017cites this paper
• The National Cancer Institute ALMANAC: A Comprehensive Screening Resource for the Detection of Anticancer Drug Pairs with Enhanced Therapeutic Activity.

  2017cites this paper
• Resistance to TRAIL Pathway-Targeted Therapeutics in Cancer

  2017cites this paper
• Proteasome inhibitor bortezomib enhances the effect of standard chemotherapy in small cell lung cancer

  2017cites this paper
• 17β-Hydroxywithanolides as Sensitizers of Renal Carcinoma Cells to Tumor Necrosis Factor-α Related Apoptosis Inducing Ligand (TRAIL) Mediated Apoptosis: Structure-Activity Relationships.

  2017cites this paper
• Therapeutic opportunities based on caspase modulation.

  2017cites this paper
• Proteomic analysis of apoptosis induction by lariciresinol in human HepG2 cells.

  2016cites this paper
• γ-secretase inhibitor I inhibits neuroblastoma cells, with NOTCH and the proteasome among its targets

  2016cites this paper
• A Bowman–Birk inhibitor induces apoptosis in human breast adenocarcinoma through mitochondrial impairment and oxidative damage following proteasome 20S inhibition

  2016influential citation
• Overcoming Cancer Cell Resistance to Death Receptor Targeted Therapies

  2015cites this paper
• Resistance of Cancer Cells to CTL-Mediated Immunotherapy

  2015cites this paper
• Clinically feasible approaches to potentiating cancer cell-based immunotherapies

  2015cites this paper
• Bortezomib enhances expression of effector molecules in anti-tumor CD8+ T lymphocytes by promoting Notch-nuclear factor-κB crosstalk

  2015cites this paper
• Targeting extrinsic apoptosis in cancer: Challenges and opportunities.

  2015cites this paper
• Sensitization of Immune-Resistant Tumor Cells to CTL-Mediated Apoptosis via Interference at the Dysregulated NF-κB/Snail/YY1/PI3K/RKIP/PTEN Resistant Loop

  2015cites this paper
• Bortezomib Improves Adoptive T-cell Therapy by Sensitizing Cancer Cells to FasL Cytotoxicity.

  2015influential citation
• HOOKING TRAIL-R2 TO ¿EDUCATE¿ IMMUNE SYSTEM TO RECOGNIZE CANCER CELLS

  2015cites this paper
• Withanolide E sensitizes renal carcinoma cells to TRAIL-induced apoptosis by increasing cFLIP degradation

  2015cites this paper
• Mechanisms of resistance to apoptosis in the human acute promyelocytic leukemia cell line NB4

  2014cites this paper
• Clinical utility of natural killer cells in cancer therapy and transplantation.

  2014cites this paper
• Rocaglamide overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance in hepatocellular carcinoma cells by attenuating the inhibition of caspase-8 through cellular FLICE-like-inhibitory protein downregulation

  2014cites this paper
• Inhibition of cancer cell growth by GRP78 siRNA lipoplex via activation of unfolded protein response.

  2014cites this paper
• Genetically engineered donor T cells to optimize graft‐versus‐tumor effects across MHC barriers

  2014cites this paper
• Medicarpin, a legume phytoalexin sensitizes myeloid leukemia cells to TRAIL-induced apoptosis through the induction of DR5 and activation of the ROS-JNK-CHOP pathway

  2014cites this paper
• XIAP-targeting drugs re-sensitize PIK3CA-mutated colorectal cancer cells for death receptor-induced apoptosis

  2014cites this paper
• TRAIL-based multivalent and multifunctional fusion proteins and liposomes for therapeutic applications

  2014cites this paper
• Overcoming Inherent Resistance to Proteasome Inhibitors in Head and Neck Cancer: Challenges and New Approaches

  2014cites this paper
• Gigantol-induced apoptosis in lung cancer cell through mitochondrial-dependent pathway

  2014cites this paper
• IL-1β and TLR4 Signaling Are Involved in the Aggravated Murine Acute Graft-versus-Host Disease Caused by Delayed Bortezomib Administration

  2014cites this paper
• Tumor-necrosis-factor-related apoptosis-inducing ligand (TRAIL).

  2014cites this paper
• Bortezomib Sensitizes Primary Meningioma Cells to TRAIL-Induced Apoptosis by Enhancing Formation of the Death-Inducing Signaling Complex

  2014cites this paper
• The TRAIL of oncogenes to apoptosis

  2013cites this paper
• Bortezomib and TRAIL: a perfect match for apoptotic elimination of tumour cells?

  2013cites this paper
• enhances natural killer cell-mediated lysis of myeloma Bortezomib down-regulates the cell surface expression of HLA-class I and

  2013cites this paper
• Doxorubicin sensitizes human tumor cells to NK and T cell-mediated killing by augmented TRAIL-receptor signaling

  2013cites this paper
• Targeting c-FLICE-like inhibitory protein (CFLAR) in cancer

  2013cites this paper
• Doxorubicin sensitizes human tumor cells to NK cell‐ and T‐cell‐mediated killing by augmented TRAIL receptor signaling

  2013cites this paper
• Review Article The TRAIL of oncogenes to apoptosis

  2013cites this paper
• Harnessing Death Receptor Signaling for Cancer Treatment

  2013cites this paper
• Adoptively transferred TRAIL+ T cells suppress GVHD and augment antitumor activity.

  2013cites this paper
• Targeting apoptosis proteins in hematological malignancies.

  2013cites this paper
• Proteasomal regulation of caspase-8 in cancer cell apoptosis

  2013cites this paper
• This information is current as TRAIL-Enhanced Apoptosis in Cancer Cells Inhibitor NPI-0052 Contributes to its Expression by the Novel Proteasome Repressor Activity of DR5 Transcription and Inhibition of Yin Yang 1-Dependent

  2013cites this paper
• transplantation continuous bortezomib administration after allogeneic bone marrow Differential effects of donor T-cell cytokines on outcome with

  2013cites this paper
• Apoptotic Potential of Cytokine Therapy for Proteasome Inhibition to Maximize the

  2013cites this paper
• Scientific heading: Neoplasia Primitive quiescent CD34 + cells in chronic myeloid leukemia are targeted by in vitro expanded natural killer cells, which are functionally enhanced by bortezomib

  2013cites this paper
• Modulating cell-to-cell variability and sensitivity to death ligands by co-drugging

  2013cites this paper
• Bortezomib enhances antigen-specific cytotoxic T cell responses against immune-resistant cancer cells generated by STAT3-ablated dendritic cells.

  2013cites this paper
• Activation of the ubiquitin proteasome pathway in a mouse model of inflammatory myopathy: a potential therapeutic target.

  2013cites this paper
• The protection and therapy effects of bortezomib in murine acute graft-versus-host disease.

  2013cites this paper
• large-cell lymphoma c-FLIP confers resistance to FAS-mediated apoptosis in anaplastic

  2012cites this paper
• Proteasome Inhibition Can Impair Caspase-8 Activation upon Submaximal Stimulation of Apoptotic Tumor Necrosis Factor-related Apoptosis Inducing Ligand (TRAIL) Signaling*

  2012cites this paper
• Signalling Molecules as Selective Targets for Therapeutic Strategies in Multiple Myeloma

  2012cites this paper
• Polyamine Metabolism in Fungi with Emphasis on Phytopathogenic Species

  2012cites this paper
• Identifikation des HIV-Proteaseinhibitors Ritonavir als Medikament mit potentieller Wirksamkeit in der Therapie der Akuten Myeloischen Leukämie in Kombination mit Proteasominhibitoren

  2012cites this paper
• Caspase control: protagonists of cancer cell apoptosis.

  2012cites this paper
• Effects of bortezomib in sensitizing human prostate cancer cell lines to NK-mediated cytotoxicity.

  2012cites this paper
• Emerging therapies in hematopoietic stem cell transplantation.

  2012cites this paper
• Polyamine Metabolism in Fungi with Emphasis on Phytopathogenic Species

  2012cites this paper
• Cell Signaling & Molecular Targets in Cancer

  2012cites this paper
• Anti-inflammatory effect of the proteasome inhibitor bortezomib on endotoxin-induced uveitis in rats.

  2012cites this paper
• Calyculin A causes sensitization to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by ROS-mediated down-regulation of cellular FLICE-inhibiting protein (c-FLIP) and by enhancing death receptor 4 mRNA stabilization

  2012cites this paper
• HDAC inhibitor modulation of proteotoxicity as a therapeutic approach in cancer.

  2012cites this paper
• Klinische Studie und experimentelle Untersuchungen zur nicht-viralen Gentherapie solider Tumoren

  2012cites this paper
• PROTEASOME REGULATION OF CASPASE-8: SIGNIFICANCE IN CANCER

  2012cites this paper
• Novel agents to improve outcome of allogeneic transplantation for patients with multiple myeloma.

  2011cites this paper
• Identification of novel therapeutic targets in mastocytosis:Inhibition of survival of neoplastic mast cells by targeting IAPs and TRAIL receptors

  2011cites this paper
• Bortezomib Primes Glioblastoma, Including Glioblastoma Stem Cells, for TRAIL by Increasing tBid Stability and Mitochondrial Apoptosis

  2011influential citation
• Targeting TRAIL towards the clinic.

  2011cites this paper
• Targeting the Anti-Apoptotic Protein c-FLIP for Cancer Therapy

  2011cites this paper
• Investigation of TRAIL resistance in ovarian cancer cell lines and translational application in primary ovarian cancer cells

  2011cites this paper
• Preclinical Development Bortezomib Sensitizes HCC Cells to CS-1008 , an Antihuman Death Receptor 5 Antibody , through the Inhibition of CIP 2 A

  2011cites this paper
• Novel insights into the synergistic interaction of Bortezomib and TRAIL: tBid provides the link

  2011cites this paper
• The ubiquitin-proteasome system (UPS) and the mechanism of action of bortezomib.

  2011cites this paper
• Targeting the extrinsic apoptosis signaling pathway for cancer therapy

  2011cites this paper
• Inhibition of the ubiquitin-proteasome system sensitizes TRAIL-resistant prostate cancer cells by up-regulation of death receptor 5.

  2011cites this paper
• Engineering of a bifunctional anti-Kv10.1 antibody for cancer therapy

  2011cites this paper
• Tumor cell-selective apoptosis induction through targeting of KV10.1 via bifunctional TRAIL antibody

  2011cites this paper
• Bortezomib Sensitizes HCC Cells to CS-1008, an Antihuman Death Receptor 5 Antibody, through the Inhibition of CIP2A

  2011cites this paper
• Advances in Viral Vector-Based TRAIL Gene Therapy for Cancer

  2011cites this paper
• Proteasome inhibition can induce an autophagy-dependent apical activation of caspase-8

  2011cites this paper
• Proteasome inhibitor sensitizes oral squamous cell carcinoma cells to TRAIL-mediated apoptosis.

  2011cites this paper
• B lymphocytes are resistant to death receptor 5-induced apoptosis.

  2011cites this paper
• Therapeutic targeting of CD95 and the TRAIL death receptors.

  2011cites this paper
• The Proteasome Inhibitor Bortezomib Sensitizes AML with Myelomonocytic Differentiation to TRAIL Mediated Apoptosis

  2011cites this paper
• Targeting death receptors to fight cancer: from biological rational to clinical implementation.

  2010cites this paper
• Review Article Isopeptidases in anticancer therapy: looking for inhibitors

  2010cites this paper
• Effects of Chemotherapy on Bone Growth and Chondrocyte Cell Death Signaling

  2010cites this paper
• Clinical Value of Absolute Lymphocyte Counts before Bortezomib-Dexamethasone Therapy in Relapsed Multiple Myeloma Patients

  2010cites this paper
• Bortezomib restores stroma‐mediated APO2L/TRAIL apoptosis resistance in multiple myeloma

  2010cites this paper
• Scatter factor protects tumor cells against apoptosis caused by TRAIL

  2010cites this paper
• Bortezomib Sensitizes Human Renal Cell Carcinomas to TRAIL Apoptosis through Increased Activation of Caspase-8 in the Death-Inducing Signaling Complex

  2010cites this paper
• Phase 1 clinical trial of bortezomib in adults with recurrent malignant glioma

  2010cites this paper